Unrelated Cord Blood Transplantation after Myeloablative Conditioning in Adults with Acute Myelogenous Leukemia  by Ooi, Jun et al.
From the
Medic
Financial d
Correspon
of He
Unive
108-8
Received J
1083-8791
doi:10.101Unrelated Cord Blood Transplantation after
Myeloablative Conditioning in Adults with Acute
Myelogenous Leukemia
Jun Ooi, Satoshi Takahashi, Akira Tomonari, Nobuhiro Tsukada, Takaaki Konuma, Seiko Kato,
Senji Kasahara, Aki Sato, Fumihiko Monma, Fumitaka Nagamura, Tohru Iseki,
Arinobu Tojo, Shigetaka AsanoWe analyzed the disease-specific outcomes of adult acute myelogenous leukemia (AML) patients treated with
unrelated cord blood transplantation (CBT) after myeloablative conditioning. Between August 1998 and Feb-
ruary 2008, 77 adult patients with AML were treated with unrelated CBT. All patients received 4 fractionated
12 Gy total body irradiation (TBI) and chemotherapy as myeloablative conditioning. The median age was 45
years, the median weight was 55 kg, the median number of nucleated cells was 2.44 107/kg, and the median
number of CD34-positive cells was 1.00  105/kg. All patients received a single and HLA mismatched cord
blood unit. The cumulative incidence of neutrophil recovery at day 50 and platelet recovery at day 200 was
94.8% and 91.7%, respectively. A higher CD34-positive cell dosewas associated with faster hematopoietic re-
covery. The cumulative incidence of grade III to IV acute graft-versus-host disease (aGVHD) and extensive-
type chronic GVHD (cGVHD) was 25.1% and 28.6%, respectively. With a median follow-up of 78 months,
the probability of event-free survival (EFS) at 5 years was 62.8%. The 5-year cumulative incidence of treatment
related-mortality (TRM) and relapse was 9.7%, 25.8%, respectively. In multivariate analyses, the risk factor
identified for event free survival (EFS) was disease status and cytogenetics. These results suggest that unre-
lated CBTafter myeloablative conditioning could be safely and effectively used for adult patients with AML.
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Although allogeneic stem cell transplantation from
a human leukocyte antigen (HLA)-identical related
donor offers a potential cure for patients with acute
myelogenous leukemia (AML), a suitably matched re-
lated donor is unavailable for approximately two-
thirds of patients. Recently, umbilical cord blood
from unrelated donors has been used as an alternative
stem cell source for adult patients [1-13]. However, re-
ports of disease-specific outcomes for adult patients
with AML after cord blood transplantation (CBT)
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ceived unrelated CBT [7,8]. Here, we updated the
results of unrelated CBT after myeloablative condi-
tioning for 77 adult patients with AML. The main pur-
pose of this retrospective single center study was to
confirm the safety and efficacy of unrelated CBT for
adult AML patients after myeloablative conditioning
as well as to identify pretransplant factors related to
the transplant outcomes on long-term follow-up.PATIENTS AND METHODS
Patients
This was a retrospective single center analysis. The
study included the data from 77 consecutively treated
AML patients, 18 years of age or older, who received
a single unit CBT after myeloablative conditioning be-
tween August 1998 and February 2008, at the Institute
of Medical Science, University of Tokyo. Diagnoses at
transplantation included de novo AML (n 5 57) and
myelodysplastic syndrome (MDS)-related secondary
AML (n 5 20). The diagnosis of AML was made for1341
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(FAB) Cooperative Group criteria [14,15]. MDS-re-
lated secondary AML was defined as AML that devel-
oped during the follow-up period of MDS. Patients
qualified as being standard risk if they were in first or
second complete remission (CR). Patients in third
CR, in relapse, or in refractory disease were classified
as being high risk. The cytogenetic subgroups accord-
ing to the SWOG/ECOG criteria [16] were favorable
in 11 patients, intermediate in 43 patients, unfavorable
in 21 patients, and unknown in 2 patients. Patients
were eligible for allogeneic transplantation in CR1 if
they had intermediate and unfavorable cytogenetic ab-
normalities. Twenty-nine patients included in our pre-
vious study were also included and extended the
follow-up [7,8]. Written informed consent for treat-
ment was obtained from all patients.
Cord Blood Unit Selection
HLA-A andHLA-B antigens were identified by se-
rological typing. HLA-DRB1 alleles were determined
by high-resolution molecular typing using polymerase
chain reaction sequence-specific primers (PCR-SSP).
Patients without a suitable closely HLA-matched fam-
ily donor were eligible for CBT, if a matched unrelated
bonemarrow donor was unavailable as a first treatment
option. If there was insufficient time for an unrelated
bone marrow donor search because of disease status
or the preliminary search indicated a low likelihood
of obtaining a matched unrelated bone marrow donor,
we attempted to locate cord blood grafts. Preferred
cord blood units matched 3 or more of 6 HLA loci
and contained a minimal cell count of 1.5 107 nucle-
ated cells/kg before freezing. All but 1 cord blood units
were obtained from cord blood banks in the Japan
Cord Blood Bank Network.
Conditioning
Seventy-two patients received 4 fractionated 12Gy
total body irradiation (TBI) on days 29, 28 or days
28 and 27, recombinant human granulocyte colony-
stimulating factor (G-CSF) combined cytosine arabi-
noside (Ara-C) and cyclophosphamide (Cy). Ara-C
was administered intravenously over 2 hours at
a dose of 3 g/m2 every 12 hours on days 26 and 25
or days 25 and 24 (total dose 12 g/m2). G-CSF was
administered by continuous infusion at a dose of 5
mg/kg/day. Infusion of G-CSF was started 12 hours
before the first dose of Ara-C and stopped at the com-
pletion of the last dose. Cy was administered intrave-
nously over 2 hours at a dose of 60 mg/kg once daily
on days 24 and 23 or days 23 and 22 (total dose
120 mg/kg). Five patient who had a cardiac damage
as a result of extensive prior therapies, received 4 frac-
tionated 12 Gy TBI on days –9 and –8, G-CSF com-
bined Ara-C 3 g/m2 every 12 hours on days –6 to –3(total dose 24 g/m2), and fludarabine 30 mg/m2 once
daily on days –5 to –3. Two days or 3 days after the
completion of conditioning, patients received a CBT.
GVHD Prophylaxis
Seventy-four patients received standard cyclospor-
ine (CsA) and methotrexate (MTX), and 3 patients re-
ceived CsA only as a graft-versus-host disease
(GVHD) prophylaxis. CsA was given intravenously ev-
ery day starting on day 21 at a dose of 3 mg/kg/day.
MTX (15 mg/m2 intravenously) was given on day 1,
and 10 mg/m2 on days 3 and 6. Once oral intake could
be tolerated, patients were administered oral CsA at
a dose of 1:2-2.5 based on the last intravenous dose.
In the absence of GVHD, CsA was tapered beginning
between weeks 6 and 9 until it could be discontinued in
the absence of chronic GVHD (cGVHD) between 6
and 12 months after transplantation. CsA was reduced
when serum creatinine levels rose above 1.5 times
baseline or other serious agent-associated toxicities oc-
curred. Physicians could freely modify the CsA dose
for patients experiencing severe acute GVHD
(aGVHD) risk for disease relapse. Corticosteroid-
based treatment was considered when grade II or
higher severe aGVHD occurred (0.5 to 2 mg/kg).
Supportive Care
All patients received G-CSF by intravenous infu-
sion starting on day 1 until durable granulocyte recov-
ery was achieved. The supportive care regimen,
including prophylaxis for infection was the same as
previously reported [10].
End Points and Definitions
Myeloid engraftment was defined as the first of 3
consecutive days during which the absolute neutrophil
count was at least 0.5  109/L. Platelet recovery time
was achieved on the first of 3 days when the platelet
count higher than 5  109/L without transfusion sup-
port. The chimerism status after CBT was determined
either by fluorescein in situ hybridization (FISH) with
a Y chromosome probe for sex-mismatchedCBT or by
quantitative PCR analysis for microsatellite DNA
markers. Primary engraftment failure was defined as
the absence of donor-derived myeloid cells on the
day of death, the day of relapse, or the day 60 in pa-
tients surviving after CBT. A second allogeneic trans-
plantation or autologous hematopoietic reconstitution
before donor-derived myeloid recovery was consid-
ered as primary engraftment failure. Both aGVHD
and cGVHD were graded according to the previously
published criteria [17,18]. Treatment-related mortal-
ity (TRM) was defined as death from any cause except
relapse. Relapse was defined by morphologic evidence
of disease in peripheral blood, bone marrow, or extra-
medullary sites. Event-free survival (EFS) was defined
Table 1. Characteristics of Patients and Cord Blood Units
Characteristics
Patients, n 77
Male/female, n 40/37
Median age, years (range) 45 (18-55)
Median weight, kg (range) 55 (36-76)
Median number of cryopreserved nucleated
cells, 107/kg (range)
2.44 (1.16-5.29)
Median number of cryopreserved CD34
positive cells, 105/kg (range)
1.00 (0.15-8.97)
Median time from diagnosis to transplantation,
months (range)
17.1 (2-103)
Recipient CMV status, positive/negative, n 64/13
Diagnosis
De novo AML, n 57
MDS-related secondary AML, n 20
Cytogenetic subgroups
Favorable, n 11
t(8;21), n 4
t(15;17), n 4
inv(16)/t(16;16), n 3
Intermediate, n 43
Normal, n 39
+8, n 4
Unfavorable, n 21
Complex, n 5
27, n 4
t(6;11), n 4
t(11;17), n 2
t(9;11), n 1
t(11;19), n 1
abn 11q23, n 1
abn 3q, n 1
abn 20q, n 1
del (9q), n 1
Unknown, n 2
Disease status at transplant
Standard risk (CR1 or CR2), n 31
High-risk (More advanced phase), n 46
Conditioning regimen
TBI+Ara-C/G-CSF+CY, n 72
TBI+Ara-C/G-CSF+Flu, n 5
GVHD prophylaxis
CyA+MTX, n 74
CyA, n 3
No. of HLA-A,B,DRB1 mismatches
1, n 16
2, n 34
3, n 23
4, n 4
ABO compatibility
Match, n 23
Mismatch, n 54
Year of transplant
1998-2002, n 32
2003-2008, n 45
CMV indicates cytomegalovirus; AML, acute myelogenous leukemia;
MDS, myelodysplastic syndrome; abn, abnormality; CR, complete remis-
sion; TBI, total body irradiation; Ara-C, cytosine arabinoside; G-CSF, re-
combinant human granulocyte colony-stimulating factor; CY,
cyclophosphamide; Flu, fludarabine; GVHD, graft-versus-host disease;
CyA, cyclosporine; MTX, methotrexate; HLA, human leukocyte antigen.
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the last observation.Statistical Analysis
Cumulative incidences were estimated for hemato-
poietic recovery, GVHD, TRM, and relapse to takecompeting risks into account. The probability of
EFS was estimated from the time of CBT according
to the Kaplan-Meier method. Variables considered in
univariate analysis were: body weight, age, recipient
sex, degree of ABO matching, degree of HLA match-
ing, recipient cytomegalovirus (CMV) serology, type
of AML (de novo AML or MDS/AML), cytogenetic
subgroups, disease status at transplant (standard or
high risk), total nucleated cell (TNC) dose, CD34-
positive cell dose, and year of transplant. Variables
with a value of P\ .05 for each end point were tested
in multivariate analysis using Cox proportional haz-
ards models. R version 2.4.1 was used for all analysis.
End points were calculated at the last contact, the
date of the last follow-up being August 1, 2008.RESULTS
Characteristics of Patients and Cord Blood
Units
The characteristics of 77 patients and cord blood
units are shown in Table 1.
Among the patients the median age was 45 years
(range: 18-55 years), the median weight was 55 kg
(range: 36-76 kg), the median number of cryopre-
served nucleated cells was 2.44  107/kg (range:
1.16-5.29  107/kg), and the median number of cryo-
preserved CD34 positive cells was 1.00  105/kg
(range: 0.15-8.97 105/kg). All patients received a sin-
gle and HLA mismatched cord blood unit.Hematopoietic Recovery
Seventy-three patients had myeloid reconstitution
and the median time to more than 0.5  109/L abso-
lute neutrophil count was 21 days (range: 16-41
days). All but 1 patients with myeloid reconstitution
showed full donor chimerism at first bone marrow
analysis around 4-6 weeks after CBT. Four patients ex-
perienced primary engraftment failure. Of the 4 pa-
tients, 1 relapsed at day 53, and 3 died at days 21, 24,
and 49 without myeloid engraftment. No patients ex-
perienced secondary engraftment failure. The cumula-
tive incidence of neutrophil recovery at day 50 was
94.8% (95% confidence interval [CI], 89.5% to
100%) (Figure 1A). In multivariate analysis, a higher
CD 34-positive cell dose was significantly associated
with faster neutrophil recovery (Table 2). A self-sus-
tained platelet counts more than 50  109/L was
achieved in 69 patients at a median time of 40 days
(range: 30-263). The cumulative incidence of platelet
recovery at day 200 was 91.7% (95% CI, 85.7% to
97.7%) (Figure 1B). In multivariate analysis, a higher
CD 34-positive cell dose and lower body weight
were significantly associated with faster platelet
recovery (Table 2).
Figure 1. Cumulative incidence of neutrophil recovery and platelet recovery. (A) Neutrophil recovery. (B) Platelet recovery.
Table 2. Multivariate Analysis of Factors Associated with
Hematopoietic Recovery, Acute GVHD, and EFS
Outcome/variables Hazard Ratio (95% CI) P
Neutrophil recovery
CD34 (+) cell
dose (105/kg)
$1.0 2.45 (2.03-2.87) <.0001
<1.0 1
Platelet recovery
CD34 (+) cell
dose (105/kg)
$1.0 2.12 (1.61-2.63) .0036
<1.0 1
Body weight (kg)
$55 0.48 (0.01-0.95) .0022
<55 1
Acute GVHD (grade III-IV)
Cytogenetics
Unfavorable 4.94 (3.59-6.29) .02
Others 1
EFS
Disease status
High risk 2.86 (1.04-7.86) .042
Standard risk 1
Cytogenetics
Unfavorable 4.94 (1.01-5.04) .048
Others 1
GVHD indicates graft-versus-host disease; EFS, event-free survival; CI,
confidence interval.
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aGVHD occurred in 69 of 73 evaluable patients.
The grading of aGVHD was grade I in 19 patients,
grade II in 41, grade III in 7, and grade IV in 2. The cu-
mulative incidence of grade II to IV and grade III to IV
aGVHD at day 100 after CBT was 81.5% (95% CI,
70.6% to 92.4%) and 25.1% (95% CI, 6.9% to
43.3%), respectively. No factor was associated with
the incidence of grade II to IV aGVHD; however, unfa-
vorable cytogenetics risk status was associated with the
incidenceof grade III to IVaGVHD(Table 2). cGVHD
occurred in 63 of 68 evaluable patients. Among 63
cGVHD patients, 21 patients were extensive type. Of
the21patients, leukemia relapse afterCBTwasdetected
in 3 patients only. Althoughmany patients responded to
cGVHD treatment including CsA and/or corticoste-
roids, 3 patients died of cGVHD. The cumulative inci-
dence of overall and extensive-type cGVHD at day 500
after CBT was 84.0% (95% CI, 74.4% to 93.6%) and
28.6% (95% CI, 17.7% to 39.5%), respectively. No
factor was associated with the incidence of overall and
extensive-type cGVHD.
Relapse
The cumulative incidence of relapse at 5 years was
25.8% (95%CI, 15.1% to 36.5%) (Figure 2A). No fac-
tor was associated with the incidence of relapse. Eigh-
teen patients relapsed after CBT. Of these patients, 13
patients had active disease at the time of transplant.
The cumulative incidence of relapse at 5 years of
MDS/AML and de novo AML was 26.4% (95% CI,
5.6% to 47.2%) and 25.8% (95% CI, 12.9% to
38.7%), respectively (P 5 .747). In subgroup analysis
according to disease status at transplant, no factor
was associated with the incidence of relapse in patients
with standard risk AML.
TRM and Causes of Death
The cumulative incidence of TRM at day 100 and
at 5 years was 9.1% (95% CI, 2.6% to 15.6%) and9.7% (95% CI, 1.8% to 16.6%) (Figure 2B), respec-
tively. No factor was associated with TRM. Nineteen
patients died. Of 19 patients, 11 patients died of re-
lapse. In 8 patients the causes of death were treat-
ment-related (organ failure n 5 2, infection n 5 3,
cGVHD with or without infection n 5 3).EFS
Of 77 patients, 51 are alive and event-free after
CBT. Median follow-up of event-free survivor was
78 months (range: 5-121 months). The probability of
EFS at 2 years and 5 years was 73.5% (95% CI,
64.2% to 84.2%) and 62.8% (95% CI, 52.1% to
75.7%), respectively (Figure 3). The probability of
Figure 2. Cumulative incidence of relapse and TRM. (A) Relapse. (B) TRM.
Biol Blood Marrow Transplant 14:1341-1347, 2008 1345Unrelated CBT for Adult AMLEFS at 5 years of standard risk patients and high-risk
patients was 82.7% (95% CI, 69.9% to 97.9%) and
49.1% (95% CI, 35.5% to 67.9%), respectively (P 5
.0065). The probability of EFS at 5 years of MDS/
AML and de novo AML was 67.4% (95% CI, 48.9%
to 93.0%) and 61.1% (95% CI, 48.6% to 76.8%), re-
spectively (P 5 .749). In multivariate analysis, high-
risk disease at transplant and unfavorable cytogenetics
risk status at diagnosis were significantly associated
with worse EFS (Table 2). In subgroup analysis ac-
cording to disease status at transplant, no factor was as-
sociated with EFS in patients with standard risk AML.Figure 3. Probability of EFS after CBT.DISCUSSION
Several studies have suggested the promising re-
sults of unrelated CBT after myeloablative condition-
ing for adult patients [1-13]. However, the factors
associated with hematopoietic recovery were not fully
described. In the report of Laughlin et al. [1] 68 adult
patients received CBT after myeloablative condition-
ing. The estimated probability of neutrophil recovery
during the first 42 days was 90% and the median
time to neutrophil recovery was 27 days. Although
CD34 positive cell dose after thawing and the close-
ness of HLA matching were not related to the speed
of neutrophil recovery, a higher number of nucleated
cells in the cord blood before freezing was associated
with faster neutrophil recovery. Because CD34 cell
dose was not always measured before freezing, the im-
pact of CD34-positive cell dose before freezing on the
speed of neutrophil recovery was unclear. However,
they found the number of nucleated cells before freez-
ing correlated with the number of CD34-positive cells
present after thawing. Recently, Arcese et al. [12] re-
ported the updated results of a large series of adult pa-
tients with different hematopoietic malignancies
transplanted in 63 centers of the Eurocord group.
One hundred seventy-one adult patients receivedCBT after myeloablative conditioning. They analyzed
outcomes and risk factors after CBT. The cumulative
incidence of neutrophil recovery at day 60 was 72%
and the median time to neutrophil recovery was 28
days. In multivariate analysis, the number of nucleated
cells at collection or freezing and the use of hemato-
poietic growth factors within 1 week after transplant
were associated with faster neutrophil recovery. In
our study, the cumulative incidence of neutrophil re-
covery at day 50 was 94.8% and the median time to
neutrophil recovery was 21 days. A higher CD 34-pos-
itive cell dose before freezing was significantly associ-
ated with faster neutrophil recovery in multivariate
analysis and all patients received G-CSF by intrave-
nous infusion starting on day 1 until durable granulo-
cyte recovery was achieved. Therefore, a higher
number of CD34 positive cells before freezing and
the use of hematopoietic growth factors may be associ-
ated with neutrophil recovery after CBT in adult set-
tings. Additionally, although use of CsA and MTX as
1346 Biol Blood Marrow Transplant 14:1341-1347, 2008J. Ooi et al.GVHD prophylaxis in adult CBT has been avoided in
several centers because of concerns regarding engraft-
ment, this GVHD prophylaxis regimen in our study
does not appear to have negatively influenced rates
and kinetics of engraftment.
In our study, the cumulative incidence of grade II
to IV aGVHD, grade III to IV aGVHD, overall and
extensive-type cGVHD was 81.5%, 25.1%, 84.0%,
and 28.6%, respectively. Although the incidence of
aGVHD and cGVHDwas relatively higher than other
reports of adult CBT [1-6,12], the cumulative inci-
dence of TRM at day 100 and at 5 years was very
low (9.1% and 9.7%, respectively). Therefore,
aGVHD and cGVHD were not related to TRM in
this study. As described before [10], immunosuppres-
sants for CBT recipients tendted to be discontinued
faster in our institution. This may be 1 of the reasons
of the relatively higher incidence of GVHD. Also,
we found no effect of HLA matching on aGVHD as
other reports of adult CBT [1,12].
In the report of Rocha et al. [6], 98 adult patients
received CBT. Among the 98 patients, 45 were AML
and 2-year leukemia-free survival was 32%. Because
this report was registry-based retrospective studies
comparing the results of unrelated CBT and unrelated
bone marrow transplantation in adults, the details of
outcomes of AMLwere not described. Recently, Brun-
stein et al. [13] reported the results of 33 adult patients
with AMLwho received CBT after myeloablative con-
ditioning at the University of Minnesota. The overall
survival is 58% and leukemia-free survival is 54%.
However, the details of transplant procedures and out-
comes were not described. Although we have previ-
ously reported the results of 29 adult patients with
AML (11 with MDS-related secondary AML, 18
with de novo AML) who received CBT after myeloa-
blative conditioning [7,8], the follow-up duration after
CBT was short and risk factors associated with trans-
plant outcomes were not analyzed. Our recent report
compared unrelated CBT and related donor grafts in
adult patients [11], including 57 patients with AML
who received CBT. However, the details of outcomes
of AMLwere not analyzed. At present, therefore, there
have been no reports detailing the long-term follow-
up results of disease-specific outcomes of adult AML
patients treated with CBT after myeloablative condi-
tioning. In this analysis, unrelated CBT after myeloa-
blative conditioning can cure approximately 65% adult
patients with AML. As previously described [10,11],
a lower TRM rate and the use of a G-CSF-combined
preparative regimen [19], which was capable of reduc-
ing the posttransplant relapse rate in refractory
myeloid malignancies, may be associated with encour-
aging outcomes in this study.
In summary, these results suggest that unrelated
CBT after myeloablative conditioning could be safely
and effectively used for adult patients with AML.A higher CD34-positive cell dose was associated with
faster hematopoietic recovery. We found no impact
of HLA matching on engraftment, GVHD, and sur-
vival. Disease status at transplant and cytogenetics
risk status at diagnosis were significantly associated
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